MTOR and cancer: Upstream regulators identified in the model included a highly significant activation of the rapamacyn-insensitive companion of mTOR (RICTOR) by Meth exposure (p = 1.68 × 10−15), and disorders assigned to cancer (p = 3.2 × 10−11), organismal injuries (p = 3.2 × 10−11), endocrine system disorders (p = 8.83 × 10−11), and metabolic disease (p = 4.3 × 10−9).